ALK and non-small cell lung carcinoma: A retrospective trial of 90 patients with ALK+ NSCLC and BM confirmed that the administration of second generation (alectinib, brigatinib, ceritinib) or third generation (lorlatinib) ALK-I could improve the clinical outcome compared to first generation ALK-I (crizotinib) in terms of the mPFS (180 vs. 45 months), 5-year PFS rate (72 vs. 43%), and 5-year OS (76% vs. 49%) [57].